Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab.
Theresa BurkardEnriqueta Vallejo-YagüeKim LauperAxel FinckhThomas HügleAndrea M BurdenPublished in: RMD open (2023)
Our longitudinal investigation suggests that BMI increase may not lead to changes in DAS28-esr in patients receiving infliximab, despite the weight-adapted dose. Yet, there may be a decrease in erosions with increasing weight non-limited to obese patients.
Keyphrases
- disease activity
- rheumatoid arthritis
- obese patients
- bariatric surgery
- body mass index
- weight loss
- systemic lupus erythematosus
- weight gain
- rheumatoid arthritis patients
- ankylosing spondylitis
- roux en y gastric bypass
- gastric bypass
- physical activity
- juvenile idiopathic arthritis
- ulcerative colitis
- cross sectional
- body weight
- interstitial lung disease
- systemic sclerosis